Canadian Breast Cancer Symposium

This interactive discussion will bring together a panel of experts to explore key questions regarding the use of ADC’s in mBC, including associated toxicities, as well as the evolving role of ADCs in breast cancer care.

Objectives:

An expert panel of speakers will:

• Review the evidence- and experience-based role of ADCs in the different subtypes of mBC
• Provide insights and tips for monitoring and managing ADC-related toxicities in routine clinical practice
• Share the potential future roles of ADCs in the treatment of breast cancer and the possible impact on the current standards of care

Program Faculty:

Program Objectives:

At the end of this session, participants will be able to:

• Explore the evolving treatment landscape of HER2− mBC, emphasizing the critical role of hormone receptors
• Clarify key differences between the mTNBC and HR+/HER2- mBC patient reflective of today’s clinical practice
• Discuss an earlier role for ADCs in the treatment of patients with mTNBC and HR+/HER2− mBC

The introduction of neoadjuvant immunotherapy for patients with early-stage triple-negative breast cancer (TNBC) has raised questions for surgeons and resulted in changes to the patient journey.

In this interactive session, a panel of experts will utilize patient cases to stimulate practical discussions regarding surgical best practices for patients with early-stage TNBC who are candidates for neoadjuvant immunotherapy. The speakers will address topics such as patient and treatment selection, the approach to surgery, and clinical considerations for patients treated with neoadjuvant immunotherapy. This session will share meaningful insights on the integration of neoadjuvant immunotherapy as a part of routine practice for patients with early-stage breast cancer.

Learning Objectives

In this interactive session, a panel of experts will utilize clinical cases to address the following key surgical considerations in patients with early-stage TNBC:

• Factors to consider during treatment selection for surgical candidates
• Practical surgical considerations for patients treated with neoadjuvant immunotherapy
• Axillary lymph node management for patients treated with neoadjuvant therapy

Program Faculty

In compliance with the Innovative Medicines Canada Code of Ethical Practices, this invitation is extended to Healthcare Professionals only.

Learning Objectives:

• Identify unmet needs and understand their implications in treating endocrine-resistant and PIK3CA-mutated breast cancer
• Gain expertise in the optimal testing paradigm for PIK3CA mutations to ensure timely diagnosis and access to personalized treatment
• Evaluate the efficacy of therapies targeting the PI3K pathway and implement strategies for managing associated adverse events including hyperglycemia

Speakers

Learning Objectives:

• Having completed this learning activity, participants should be better able to:
• Use the latest screening guidelines to assess risk features of disease recurrence in patients with eBC (e.g., biomarkers, lymph node involvement)
• Discuss the effectiveness of CDK4/6 inhibitor therapy in the context of the latest clinical trial and real-world evidence, and formulate individual treatment plans
• Compare strategies to anticipate and manage adverse events associated with CDK4/6 inhibitors within the Canadian healthcare system
• Describe how to develop sequencing strategies for patients who experience disease progression while undergoing adjuvant therapy, in light of the most recent available evidence

Program Faculty:

Overview:

Join us for a dynamic discussion on recurrence risk in HR+/HER2- EBC, identifying patients who might benefit from CDK4/6i adjuvant therapy, and optimizing the care of patients of such patients through a multidisciplinary lens.

Learning Objectives:

• Describe the cumulative risk of disease recurrence in patients with HR+ EBC treated with adjuvant endocrine therapy
• Identify patients who are eligible for and could benefit from the addition of CDK4/6i to adjuvant endocrine therapy
• Apply strategies to optimize the care of patients with EBC in the adjuvant setting within the multidisciplinary team

Speakers